Reference record
A Phase Ia, Dose-finding Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults
University Hospital Tuebingen
First Published (first received 2022 May 25)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT05389319)
Trial registry recordNo Results
This is an open-label, first-in-human, dose-finding study to evaluate the safety and
immunogenicity of a booster vaccination of Prime-2-CoV_Beta in healthy participants who had
received the full course of vaccination, including booster vaccination (i.e., having received
3 doses) with the Pfizer/BioNTech-BNT162b2 vaccine (Comirnaty)